Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

CDRH compliance chief to retire: Tim Ulatowski will retire from FDA at the end of the year, the veteran agency staffer announced in an April 12 memo to staff. Ulatowski said he made the decision before the new FDA administration came on board last year. An opening for the CDRH Office of Compliance director position was posted April 12 and FDA will review candidates and select a replacement "over the next few weeks," Ulatowski predicts. A smooth transition is important given CDRH's ambitious agenda for the coming years, he said (1"The Gray Sheet" April 5, 2010). "A break in permanent leadership for maybe a few months while all this is occurring would not be helpful," Ulatowski said in the memo. Once the new director is hired, Ulatowski will shift to a temporary advising role until his retirement. He has been with FDA since 1974 and with the Office of Compliance since 2003
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT028831

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel